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http://www.clinicalepigeneticsjournal.com/content/4/1/15RESEARCH Open AccessIGF2/H19 hypomethylation is tissue, cell, and CpG
site dependent and not correlated with body
asymmetry in adolescents with Silver-Russell
syndrome
Kai Kannenberg1*, Karin Weber1, Cathrin Binder1, Christina Urban1, Hans-Joachim Kirschner2 and Gerhard Binder1Abstract
Background: Silver-Russell syndrome (SRS) is characterized by severe intrauterine and postnatal growth failure and
frequent body asymmetry. Half of the patients with SRS carry a DNA hypomethylation of the imprinting center
region 1 (ICR1) of the insulin-like growth factor 2 (IGF2)/H19 locus, and the clinical phenotype is most severe in
these patients. We aimed to elucidate the epigenetic basis of asymmetry in SRS and the cellular consequences of
the ICR1 hypomethylation.
Results: The ICR1 methylation status was analyzed in blood and in addition in buccal smear probes and cultured
fibroblasts obtained from punch biopsies taken from the two body halves of 5 SRS patients and 3 controls. We
found that the ICR1 hypomethylation in SRS patients was stronger in blood leukocytes and oral mucosa cells than
in fibroblasts. ICR1 CpG sites were affected differently. The severity of hypomethylation was not correlated to body
asymmetry. IGF2 expression and IGF-II secretion of fibroblasts were not correlated to the degree of ICR1
hypomethylation. SRS fibroblasts responded well to stimulation by recombinant human IGF-I or IGF-II, with
proliferation rates comparable with controls. Clonal expansion of primary fibroblasts confirmed the complexity of
the cellular mosaicism.
Conclusions: We conclude that the ICR1 hypomethylation SRS is tissue, cell, and CpG site specific. The correlation
of the ICR1 hypomethylation to IGF2 and H19 expression is not strict, may depend on the investigated tissue, and
may become evident only in case of more severe methylation defects. The body asymmetry in juvenile SRS patients
is not related to a corresponding ICR1 hypomethylation gradient, rendering more likely an intrauterine origin of
asymmetry. Overall, it may be instrumental to consider not only the ICR1 methylation status as decisive for IGF2/H19
expression regulation.
Keywords: Silver-Russell syndrome, DNA methylation, Body asymmetry, Skin fibroblast culture, IGF-IIBackground
Silver-Russell syndrome (SRS; OMIM 180860) is a spor-
adically occurring, genetically and clinically heteroge-
neous disorder. It is diagnosed on the basis of the
combination of intrauterine growth retardation, severe
short stature, characteristic triangular face, relative
macrocephaly, body asymmetry, underweight, and* Correspondence: kai.kannenberg@med.uni-tuebingen.de
1University Children’s Hospital Tübingen Pediatric Endocrinology, 72076
Tübingen, Germany
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distribution, and reproduction in any mediumseveral minor abnormalities [1-3]. The relative limb
length differences in asymmetric SRS patients are
present at birth and stay stable during the growth
process [4]. Short stature in SRS can be treated with
pharmacological doses of recombinant growth hormone
[5]. There is no apparent hormone deficiency. In con-
trast, insulin-like growth factor (IGF)-I and IGF-II, and
insulin-like growth factor binding protein 3 (IGFBP-3)
serum levels are frequently inappropriately high in rela-
tion to the short stature, suggesting some kind of IGF-I
insensitivity [6,7].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Kannenberg et al. Clinical Epigenetics 2012, 4:15 Page 2 of 12
http://www.clinicalepigeneticsjournal.com/content/4/1/15In SRS, hypomethylation of the paternal allele of the
telomeric imprinting center region 1 (ICR1, also named
H19DMR) within the IGF2/H19 locus on 11p15 can be
found in approximately 50% of the patients [8]. The clin-
ical phenotype is most severe in these SRS patients
[7,9-11]. Since in general, no complete ICR1 demethyla-
tion is observed, a mosaic distribution of the defect is
assumed. The centromeric imprinting center region 2
(ICR2) within the KCNQ1 gene on 11p15 is hypomethy-
lated in less than 5% of ICR1 hypomethylated SRS
patients [12,13]. Maternal uniparental disomy of chromo-
some 7 is present in roughly 10% of SRS cases [14]; the
remaining cases are of unknown etiology.
ICR1 controls the imprinting of IGF2 [15,16] on the
paternal allele and of H19 on the maternal allele. The
IGF2-encoded IGF-II is an important growth factor for
intrauterine development [17,18]. H19 encodes a non-
translated RNA whose function is unknown [19-21]. The
ICR1 hypomethylation of the paternal allele found in
SRS is thought to result in a relevant suppression of the
normal IGF2 expression. The hypomethylated paternal
ICR1 enables binding of the insulator protein CTCF
(CCCTC-binding factor) which suppresses IGF2 and
promotes H19 expression via relocation of enhancer ele-
ments distal to H19 from the IGF2 promotor to the H19
promotor [22-24]. An imprinting defect in the opposite
direction, resulting in IGF2 overexpression in response
to ICR1 hypermethylation, is present in a subgroup of
patients with the overgrowth syndrome described by
Beckwith and Wiedemann (BWS; OMIM 130650)
[25-27].
In contrast to the genetic knowledge on the etiology of
SRS, experimental data on cellular downstream effects
of the epimutations are scarce. Reduced IGF2 expression
was reported in skin fibroblasts from two relevant SRS
patients [8] and in placentas from three newborn babiesTable 1 Clinical characteristics of the patients with Silver-Rus
Patient Unit S1
Duration of gestation weeks 40
Birth length cm (SDSa) 40 (−6.01) 38
Birth weight g (SDSa) 1560 (−5.68) 138
Triangular face +
Body asymmetry +




Buccal smear probes +
Skin biopsies +
aStandard deviation scores according to Niklasson et al. [30].
b♂:male, ♀:female.with SRS and ICR1 hypomethylation [28]. However,
serum IGF-II levels of children with SRS are normal
[6,9] which may reflect the non-imprinted, biallelic post-
natal IGF2 expression in the liver [29].
This study was undertaken to test the following three
hypotheses. A) The body asymmetry in adolescent SRS
patients with ICR1 hypomethylation is reflected by an
ICR1 methylation gradient between the short and the
long body side, with stronger hypomethylation at the
shorter side. B) On the cellular level, ICR1 hypomethyla-
tion leads to reduced IGF2 and enhanced H19 expres-
sion. C) IGF-I insensitivity contributes to the etiology of
SRS in ICR1 hypomethylated patients by reducing cell
proliferation in response to IGF-I stimulation. Our ex-
perimental approach was to examine the degree of ICR1
hypomethylation in the tissue of the two asymmetric
halves of children with SRS and to establish a fibroblast
culture model system from bilaterally taken skin biopsies
of SRS patients for the analysis of the relationship be-
tween ICR1 methylation status, IGF2/H19 expression,
and cell proliferation.
Results
ICR1 hypomethylation in various tissues and in both body
halves
For the comparison of the degree and the characteristics
of ICR1 hypomethylation in different tissues we examined
blood leukocytes, cells from the oral mucosa (buccal
smears) and cultured fibroblasts (forearm skin biopsies).
Smears and biopsies were taken from both sides of the
body in each individual (Table 1) to search for epigenetic
or functional differences in the two asymmetrically devel-
oped halves of the body in SRS. In this first comparison,
results are the mean of the methylation values of the
CpG sites M1-M5 (for genomic location see Figure 1
and Additional file 1) and are used as the parameter tosell syndrome (SRS)
S2 S3 S4 S5
39 39 34 39
(−6.14) 45 (−2.35) 34 (−4.52) 44 (−3.18)
0 (−5.35) 1960 (−3.46) 955 (−3.81) 1800 (−4.23)
+ + + +
+ + + +
left left right left
♀ ♀ ♀ ♂
16.6 9.2 9.7 16.3
+ + + +
+ + + +
+ + - +
Figure 1 Genomic location of MS-MLPA ICR1 sites M1 to M5 and of CTCF binding sites 1 to 7. Genomic position (upright numbers) of
CpG sites M1-5 are shown according to basic local alignment search tool (BLAST) search with the relevant sequences provided by the
manufacturer (see also Additional file 1). Exon sequences were obtained from NM_000612.4 (IGF2) and NR_002196.1 (H19) at NCBI Nucleotide and
matched against human genome build GRCh37 from the Genome Reference Consortium accessible at http://www.ensembl.org. CCCTC-binding
factor (CTCF) site sequences from Bell et al. [22] were matched to the genomic sequence by BLAST search (Additional file 1). Figure adapted and
modified from Kannenberg et al. [31]. MS-MLPA, methylation-specific multiple ligation-dependent probe amplification.
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methylation analysis was done by methylation-specific
multiplex ligation-dependent probe amplification (MS-
MLPA).
In SRS patients S1 to S3 and S5, ICR1 was significantly
hypomethylated in all three tissues examined when com-
pared with the controls K1 to K3. The ICR1 hypomethy-
lation was strongest in blood leukocytes (25 versus 56%;
P < 0.001), moderately less severe in oral mucosa cells
(32 versus 60%; P < 0.001), and mildest in cultured skinTable 2 Imprinting center region 1 (ICR1) methylation levels
controls
Blood Buccal
SRS patients Short sidea
S1 18b ± 2 (4)c 32 ± 4 (3)
S2 25 ± 2 (3) 25 ± 1 (3)
S3 36 ± 2 (3) 43 ± 1 (3)
S4 21 ± 2 (4) 28 ± 1 (2)
S5 27 ± 3 (5) 34 ± 3 (2)
Mean S1 to S5 25 ± 5e 32 ± 7
32f
Controls L
K1 52 ± 2 (2) 64 ± 0 (2)
K2 53 ± 5 (2) 53 ± 3 (3)
K3 64 ± 4 (3) 61 ± 5 (2)
Mean K1 to K3 56 ± 5 60
aFor location of short side see Table 1; bMS-MLPA determined methylation level in%
dnd=not done; eP (S1 to S5: K1 to K3)blood = 0.00077;
fP (S1 to S5: K1 to K3)buccal smeafibroblasts (43 versus 54%; P= 0.022) (Table 2 and
Figure 2A). In contrast, ICR2 methylation was normal in
all tissues of the SRS patients (see Additional file 2).
When comparing the methylation values measured in
tissues from the two asymmetric halves of the body,
there was no clear-cut difference observed. In oral mu-
cosa cells, mean ICR1 methylation values from the short
and the long side of the asymmetric body of the SRS
patients were comparable (Table 2). In fibroblasts from
the shorter forearm, ICR1 hypomethylation was morein patients with Silver-Russell syndrome (SRS) and
smears Skin fibroblasts
Long side Short side Long side
33 ± 4 (4) 40 ± 2 (3) 48 ± 5 (3)
25 ± 3 (3) 38 ± 1 (2) 30 ± 1 (2)
46 ± 2 (3) 48 ± 5 (5) 58 ± 1 (2)
35 ± 5 (2) ndd nd
23 ± 1 (2) 36 ± 1 (2) 44 ± 1 (2)
32 ± 9 41 ± 5 45± 12
± 8 43g ±9
R L R
69 ± 2 (2) 51 ± 2 (2) nd
55 ± 2 (4) 56 ± 3 (2) 57 ± 4 (2)
60 ± 4 (2) 53 ± 1 (2) 52 ± 2 (2)
± 6 54 ± 3
(100%= fully methylated); cnumber of MS-MLPA determinations in brackets;
rs = 0.0000024;
gP (S1 to S5: K1 to K3)skin fibroblasts = 0.022. L, left side; R, right side.
Figure 2 Imprinting center region 1 (ICR1) hypomethylation in
patients with Silver-Russell syndrome (SRS) in different tissues.
The mean ICR1 (A) and single ICR1 sites M1 to M5 (B) methylation
values of SRS patients S1 to S5 and control patients K1 to K3 are
plotted for the different tissues investigated. *P< 0.05, ** to
******P<0.01 to P< 1E-6. See Additional file 3 for mean single-site
methylation data in tabular form.
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but not in patient S2 (Table 2).Hypomethylation of single CpG sites within ICR1
The above used mean from the CpG sites M1 to M5
does not reflect the whole complexity of the ICR1 hypo-
methylation observed in SRS. Therefore, we calculated
CpG site-specific methylation values as well (Figure 2B).
Only sites M2 and M3 were significantly hypomethy-
lated in all tissues from SRS patients investigated. Sites
M1 and M4 were found to be significantly hypomethy-
lated in blood leukocytes and oral mucosa cells, but not
in cultured fibroblasts. Site M5 was normally methylated
in all tissues examined.
More detailed analysis showed that in blood leukocytes
and oral mucosa cells of all five SRS patients M1 to M3
methylation levels were well below the control range (see
Additional file 4), while in fibroblasts some values not
only for M1, but also for M2 and M3 methylation, were
in the range of the controls. There was no correlation be-
tween the degree of hypomethylation in bilateral oral mu-
cosa or skin fibroblasts probes and body asymmetry, at
any sites in the relevant SRS patients (data not shown).ICR1 methylation pattern of clones originating from a
single fibroblast
The above shown variable degrees of hypomethylation
are thought to reflect a mosaicism of cells carrying ab-
sent, low, or normal levels of methylation of the CpG
sites M1 to M4. Therefore, isolation and propagation
of one single cell out of this cell mosaic should extin-
guish mosaicism and enable the characterization of the
methylation pattern within this single cell.
The patterns of single CpG site hypomethylation in
clonal cultures from patient S2 showed substantial vari-
ability. In some of the cell clones from patient S2, the
degree of hypomethylation at the CpG sites M2 to M4
was almost 0%, while other clones from the same patient
showed normal methylation values at these sites
(Table 3). CpG site M1 was also demethylated in most
of the control clones tested, corresponding to the low
M1 methylation level of the culture of origin, control pa-
tient (K1), left side (L). The methylation level of site M5
was not different between clones from SRS patient S2
and from the control patient.IGF2 expression in cultured skin fibroblasts from SRS
patients
Relative IGF2 and H19 mRNA levels in fibroblasts
varied over a broad range. Control cultures showed
poor quantitative correlation of IGF2 and H19
mRNA levels (Figure 3A), while in SRS cultures
there was a positive correlation of both mRNA ana-
lytes. An H19 mRNA excess or an IGF2 mRNA defi-
ciency in SRS patients compared to controls was not
evident. The degree of ICR1 hypomethylation (mean
of M1 to M5 or M2 alone) did not predict the
amount of IGF2 mRNA produced (Figures 3B and
3C). Control experiments (priming cDNA synthesis
with random hexamers instead of oligo dT) resulted
in comparable results (see Additional file 5) with
some larger variations in the microRNA precursor
H19 mRNA. Also, experiments using a different PCR
primer pair for the amplification of IGF2 cDNA con-
formed to the reported measurements (see Additional
file 5).IGF-II secretion of cultured skin fibroblasts
Levels of secreted IGF-II were not significantly different
(P > 0.6) between fibroblast cultures from SRS patients
(mean 5.4 ± 2.3 ng/ml) and controls (5.0 ± 1.0 ng/ml)
(Table 4). Fibroblasts obtained from the shorter arm
were associated with lower IGF-II concentrations in two
patients, and in the other 2 patients, with higher IGF-II
concentrations than fibroblasts obtained from the longer
arm of the respective individual.
Table 3 M1 to M5 methylation levels of clonal fibroblast cultures from Silver-Russell syndrome (SRS) patient S2 and
control patient K1
Fibroblast culture Origin/clone na % Methylation of individual MS-MLPA sites
M1 M2 M3 M4 M5
S2L (short side) origin 2 4b ± 3 13 ± 8 17± 6 62± 10 97 ± 6
1 2 26 ± 8 2± 1 45± 5 47± 1 114 ± 7
2 2 66 ± 10 1± 1 58± 7 66± 2 118 ± 5
3 2 1± 1 0± 0 6± 1 43± 5 90± 4
4 2 34 ± 3 0± 0 49± 7 44± 8 100 ± 3
S2R (long side) origin 2 1 ± 1 3± 0 15± 6 31± 5 100 ± 1
1 2 0± 0 0± 0 5± 2 0± 0 99± 13
2 2 1± 1 0± 0 10± 2 44± 1 107 ± 4
3 2 0± 0 0± 0 1± 1 2± 2 84± 13
4 2 0± 0 4± 4 11± 1 6± 1 78 ± 7
K1L origin 2 17 ± 7 35± 8 43± 11 70 ± 6 92± 21
1 3 0 ± 0 44 ± 3 59 ± 8 44 ± 7 120 ± 10
2 3 0 ± 0 51 ± 6 51 ± 5 75 ± 10 99 ± 8
3 2 1± 1 33± 10 44 ± 5 49± 1 99± 10
4 2 0 ± 0 44 ± 2 43 ± 5 60 ± 7 82 ± 5
5 3 38 ± 2 45± 6 49± 1 43± 9 100 ± 19
6 3 1 ± 0 28 ± 6 61 ± 7 81 ± 7 94 ± 9
7 2 1± 1 26± 1 39± 2 102 ± 4 91± 3
aNumber of MS-MLPA determinations; bMS-MLPA determined methylation level in%. MS-MLPA, methylation-specific multiple ligation-dependent probe
amplification; L, left; R, right.
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fibroblasts
Basal fibroblast proliferation rates in standard culture
medium were tested at low and high initial cell densities
and for different periods of time after seeding the cells.
There were no significant differences between SRS pa-
tient fibroblasts and control fibroblasts (Table 5). Stimu-
lating fibroblast proliferation by adding recombinant
human IGF-I or IGF-II, respectively, to the culture
medium resulted in comparable dose response curves
(Figure 4) with no significant differences regarding EC50
values or proliferation responses at the diverse hormone
concentrations tested.
Discussion
Studying five asymmetrically growing adolescent chil-
dren with SRS in comparison to three control probands
we observed a strong tissue-dependence of the degree of
ICR1 hypomethylation within the IGF2/H19 locus. Body
asymmetry was not correlated with a different degree of
ICR1 hypomethylation found in tissue probes taken from
both sides of the body. Detailed methylation analysis
revealed differential hypomethylation of the five exam-
ined ICR1 CpG sites in all patients. Analysis of cultured
skin fibroblasts after clonal expansion confirmed the
complex cellular mosaicism of the ICR1 hypomethyla-
tion. IGF2 expression, IGF-II secretion, and cellproliferation of cultured fibroblasts from SRS patients
were not different to controls and without a significant
difference in samples taken from the two asymmetric
body halves of the same patient.
ICR1 hypomethylation was most severe in blood leu-
kocytes, less severe in oral mucosa cells, and least severe
in cultured skin fibroblasts. It is unlikely that the moder-
ate ICR1 hypomethylation in fibroblasts was due to
effects of cell culture on ICR1 methylation, that is, a pre-
ferential loss of fibroblasts with ICR1 hypomethylation
during culture or some general healing effect of cell cul-
ture on ICR1 hypomethylation. First, clonal fibroblast
cultures prepared from original cultures showed virtually
absent methylation for several ICR1 CpG sites. Second,
another study [8] reported an even stronger hypomethy-
lation in cultured skin fibroblasts of one SRS patient
compared to blood leukocytes. Third, two recent micro-
array studies [32,33] gave no evidence that the methyla-
tion of two ICR1 CpG sites is significantly different
between young (passages 2 to 3) and long-term (pas-
sages 21 to 48) skin fibroblast cultures overall from five
normal subjects (see Additional file 9 for data and links
to the relevant datasets), indicating that normal ICR1
methylation is not affected by skin fibroblast cell culture.
Reports on the various degrees of hypomethylation in
different tissues in SRS are inconsistent. As already men-
tioned above, Gicquel et al. [8] found a more severe
Figure 3 IGF2 and H19 expression in skin fibroblast cultures. IGF2 and H19 mRNA levels were determined by real time (RT)-PCR. See
Additional file 6 for data in tabular form. (A) IGF2 and H19 expression values from the individual cultures are related. Virtually no correlation was
present for the control cultures (rPearson =−0.12) and a positive correlation for the Silver-Russell syndrome (SRS) cultures (rPearson = 0.96). (B) The
IGF2 expression values are related to the imprinting center region 1 (ICR1) methylation value (mean of MS-MLPA sites M1 to M5) from the same
culture (Table 2). (C) The IGF2 expression values are related to the methylation values from site M2 only (see Additional file 4 for tabular
methylation data).
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blood leukocytes in a single patient with SRS. Yamazawa
et al. [28] reported on a stronger hypomethylation in
blood leukocytes than in preserved placental tissues
from three patients. Begemann et al. [13] observed a
more severe hypomethylation in blood leukocytes than
in buccal smears in two SRS patients and the opposite
for one additional patient. These contrasting findings
may reflect different experimental settings or the pres-
ence of real individual characteristics of the mosaic
hypomethylation. In the majority of the reported cases,
however, the degree of ICR1 hypomethylation was posi-
tively correlated to the degree of the proliferation rate of
the specific tissue. If this holds true for a larger group
of patients, it may indicate that the mechanism of
hypomethylation (defective maintenance of normalmethylation or defective repair of aberrant methylation)
can be overcome by slow proliferation.
The methylation of the ICR2 within the IGF2/H19
locus was found to be unchanged in all tissues from SRS
patients, confirming results from previous studies in
which concomitant ICR1 and ICR2 hypomethylation
was shown to be a rare event [12,13].
Three-quarters of the SRS patients with ICR1 hypo-
methylation present with body asymmetry (76% [9]; 71%
[7]; 77% [11]; 68% [3]). Our hypothesis of a mosaicism
with a higher degree of ICR1 hypomethylation at the
shorter body side could not be confirmed in bilaterally-
obtained probes of oral mucosa and skin. Our observation
renders it unlikely that the postnatal persistence of asym-
metric growth in the adolescent SRS patients [4] is due to
a persisting long side-short side ICR1 hypomethylation
Table 4 IGF-II concentrations in supernatant from
cultured skin fibroblasts
IGF-II (ng/ml)
SRS patients Short sidea Long side
S1 5.6b ± 0.4 4.7 ± 0.2
S2 8.2 ± 1.1 6.4 ± 0.1
S3 3.4 ± 0.3 8.8 ± 0.9
S5 2.6 ± 0.1 3.4 ± 0.3
Mean S1 to S5 4.9c ± 2.5 5.8 ± 2.3
5.4 ±2.3
Controls L R
K1 6.4 ± 0.2 ndd
K2 5.1 ± 1.8 3.9 ± 0.6
K3 5.4 ± 0.8 4.1 ± 0.4
Mean K1 to K3 5.0 ±1.0
aFor location of short body side see Table 1; bmean of two experiments; cP-
value > 0.6 for comparison between short side and long side, as well as for
comparison between SRS and control groups; dnd= not done. SRS, Silver-
Russell syndrome; L, left; R, right.
Figure 4 IGF-I and IGF-II stimulated proliferation of skin
fibroblasts. Skin fibroblasts grown 4 days in culture were treated
with various concentrations of recombinant IGF-I (A) and IGF-II (B)
until (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2 H-tetrazolium, inner salt (MTS) test at day 7. Relative
proliferation values were calculated by normalization to cultures
treated with diluent (culture medium) only. For IGF-I stimulation,
mean EC50 values of 81 ± 30 ng/ml (S1 to S5) and 62± 25 ng/ml (K1
to K3) were obtained; PIGF-I (S1-5:K1-3) = 0.246. For IGF-II stimulation,
mean EC50 values of 168± 96 ng/ml (S1 to S5) and 114 ± 33 ng/ml
(K1 to K3) were obtained; PIGF-II (S1-5:K1-3) = 0.261. See Additional files
7 and 8 for tabular data. S, patients with Silver-Russell syndrome; K,
control patients.
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metry may be restricted to the intrauterine development.
The ICR1 CpG sites M1 to M4 were differentially
hypomethylated in the three tissues examined from SRS
patients. This and the different patterns of demethylated
and normally methylated sites in clonal skin fibroblast
cell lines indicate the presence of a complex cellular mo-
saic in SRS, consisting of multiple different cells in terms
of the number and position of CpG sites affected from
hypomethylation within the ICR1. Interestingly, tissue-
dependent variability of methylation was found also in
control patients for some CpG sites (M1, M5). The last
finding emphasizes the importance of methods with spe-
cificity for single CpG sites to clearly define the extent
of hypomethylation in SRS patients.
Information on IGF2 and H19 expression in tissue
from SRS patients is scarce. In cultured skin fibroblasts
from two SRS patients [8] and in paraffin-embedded
placental tissue from three SRS fetuses [28] a correl-
ation of ICR1 hypomethylation with suppressed IGF2
expression was shown. In contrast, we observed no
ICR1 hypomethylation-dependent reduction of IGF2 ex-
pression in cultured skin fibroblasts from SRS patients.Table 5 Basal proliferation of skin fibroblast cultures
Number of seeded cells ODd4/ODd1
a
S1 to S5 K1 to K3
Mean (n= 16)c Mean (n= 10)d
200 cells/well 4.25 ± 2.04 5.33 ± 1.67
1600 cells/well 2.92 ± 1.22 3.54 ± 1.01
aMean absorption from (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(
divided by that after 1 day in culture; bmean absorption from MTS test after 7 days
the cultures from patients S1, S2, S3, and S5 L/R; dtwo tests done for each of the cu
K, control patient; L, left side; R, right side.Possible explanations for this discrepancy are outlined
as follows.
The major difference of the study by Gicquel et al. [8]
to ours is the different degree of the ICR1 hypomethyla-
tion of the SRS patients investigated. The cultured skin
fibroblasts of our four SRS patients exhibited a mean
ICR1 methylation level of 43%, ranging from 30 to 58%
according to MS-MLPA. In contrast, Gicquel et al. [8]
studied cultured skin fibroblasts from a single SRS pa-
tient with an ICR1 methylation level (determined by
southern blot analysis) of only 10% and from a second
patient with that same very low methylation level in
blood leukocytes (corresponding value for fibroblastsODd7/ODd4
b
T- test S1 to S5 K1 to K3 T- test
P Mean (n= 16)c Mean (n = 10)d P
0.17 2.41 ± 1.33 2.09 ± 0.74 0.49
0.19 1.36 ± 0.26 1.33 ± 0.40 0.81
4-sulfophenyl)-2 H-tetrazolium, inner salt (MTS) test after 4 days in culture
in culture divided by that after 4 days in culture; ctwo tests done for each of
ltures from K1L, K2, and K3 L/R. S, patient with Silver-Russell syndrome;
Kannenberg et al. Clinical Epigenetics 2012, 4:15 Page 8 of 12
http://www.clinicalepigeneticsjournal.com/content/4/1/15was not reported). Therefore, ICR1 hypomethylation in
cultured skin fibroblasts of SRS patients may only be
functionally relevant in terms of reducing IGF2 expres-
sion when falling below a certain threshold not reached
in the individual specimens collected for our study. This
interpretation is supported by the finding that the clin-
ical phenotype in SRS patients with ICR1 hypomethyla-
tion is more severe in the presence of a very low
methylation level (< 9%) than in patients with a less pro-
nounced ICR1 hypomethylation [11].
In the other study linking ICR1 hypomethylation to
decreased IGF2 expression, RNA was extracted from
paraffin-embedded placental tissues from three pregnan-
cies with SRS fetuses [28]. In contrast to our study, the
ICR1 methylation indices were determined with the
combined bisulfite restriction analysis (COBRA). In
addition, one has to note that RNA quantification from
paraffin-embedded placental tissues is technically diffi-
cult, potentially influencing the results [28]. The mea-
sured placental ICR1 methylation indices were at 30 to
33% and therefore at the lower end of the ICR1 methyla-
tion levels for cultured skin fibroblasts from SRS
patients in our study. The relevant methylation-sensitive
restriction site was juxtaposed to site M2 from our
study. The reduced IGF2 expression for the hypomethy-
lated placental specimens found by Yamazawa et al. [28]
may indicate a tighter ICR1 control of IGF2 expression
in the placenta than in the cultured skin fibroblasts we
investigated. In line with this, appropriate IGF2 expres-
sion and therefore also its regulation is well known to be
of pivotal importance for normal placental development
[18,34].
A model in which the ICR1 methylation status recip-
rocally regulates IGF2 and H19 expression [22-24,35]
was not supported by our data, since we did not find a
corresponding inverse correlation of the two mRNA
analytes. In accordance with this, others have experi-
mentally shown that the binding of the insulator protein
CTCF to unmethylated ICR1, suggested to be mechanis-
tically linked to downregulation of IGF2 expression and
upregulation of H19 expression, did not result in the
predicted gene expression in diverse human tissues [36].
Also, in one of the studies already mentioned above [28],
IGF2 suppression in placental specimens from SRS
patients was not accompanied by enhanced H19 expres-
sion. Clearly, more tissue-related experiments will be ne-
cessary to further understand cellular downstream
effects of the ICR1 hypomethylation in SRS patients.
Theoretically, changes in so far unknown regulatory ele-
ments acting at the IGF2/H19 locus in addition to ICR1
methylation, including other chromatin modifications,
may exist in SRS patients. A further level of regulation
would potentially also explain the large variations we
found in IGF2 and H19 expression in controls.Normal to high IGF-I and IGF-II serum levels in SRS
patients with ICR1 hypomethylation [6,7] in comparison
to age- and stature-related references hinted at some de-
gree of IGF-I insensitivity. In a single case report [37] on
cultured skin fibroblasts from a SRS patient with ICR1
hypomethylation and extraordinary high IGF-I serum
level, a reduced proliferative response to IGF-I stimula-
tion compared to controls was found. In contrast, we
found normal proliferation of fibroblasts from four SRS
patients in response to IGF-I and IGF-II stimulation.
These results render more unlikely the hypothesis that
decreased IGF-I sensitivity is a leading cause of growth
failure in SRS.
Potential limitations of our study are as follows. The
SRS group in this study consisted of five patients (three
female, two male) and was compared with three control
subjects (all male), and some caution regarding possible
gender differences, albeit not observed by us, should re-
main. In addition, the number of individuals examined
in our study was limited by the fact that biopsy material,
including skin specimens, is difficult to obtain from ju-
venile individuals. Finally, for the study of the growth
deficit in SRS the availability of bone tissue would be de-
sirable, but bone biopsy however, would only be possible
in the very rare SRS patients undergoing bone surgery
for medical reasons.
Conclusions
ICR1 hypomethylation in SRS patients is tissue- and
CpG site-dependent and shows a complex cellular mo-
saicism. Asymmetric growth in SRS children is not
related to a more pronounced ICR1 hypomethylation at
the shorter side of the body, rendering more likely, intra-
uterine developmental defects as causative for asym-
metry. An influence of ICR1 hypomethylation on IGF2
expression in SRS may only become evident in the case
of a strong hypomethylation and may be more prevalent
in placental tissue than in the cultured skin fibroblasts
from the adolescent patients we investigated. An un-
altered fibroblast proliferation response to exogenous
IGF-I and IGF-II do not support the hypothesis of IGF-I
insensitivity in SRS. The establishment of clonal cell cul-
tures is likely to overcome some of the inherent obsta-
cles in studying the effects of an epigenetic mutation
expressed as a cellular mosaic.
Availability of supporting data
The data sets supporting the results of this article are
included within the article (and its additional files).
Methods
Individuals
The protocol of the study was reviewed by the Ethics
Committee of the Medical Faculty of Tübingen. All
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gave their written informed consent before enrolment.
The five SRS patients with ICR1 hypomethylation
(identified as S1 to S5; 9.2 to 16.6 years of age, two male)
were recruited at our Pediatric Endocrinology Out-
patient Department. Body asymmetry was documented
by photography of the hands of each patient. Clinical
characteristics of the patients are shown in Table 1.
Three healthy children (identified as K1 to K3; all
male; 14.0, 14.7, and 15.0 years of age) served as con-
trols. These children were recruited at our Pediatric Sur-
gery Department where they underwent operation under
anesthetic for removal of metals or wires after arm frac-
ture healing.
A blood sample and two buccal smears from both
cheeks were obtained from all individuals. Skin punch
biopsies (2 mm punches from Stiefel, Offenbach, Ger-
many) from both forearms were obtained from patients
S1, S2, S3 and S5, and from the controls K2 and K3.
From control K1, a skin biopsy was obtained only from
one arm. No skin biopsy was obtained from patient S4.
Genomic DNA preparation
Genomic DNA was prepared from whole blood (Gen-
omic DNA Extraction Kit; Macherey & Nagel, Düren,
Germany), buccal smears (Puregene Buccal Cell Core
kit; Qiagen, Hilden, Germany), and cultured fibroblasts
(DNeasy Tissue Kit; Qiagen).
Methylation analysis by MS-MLPA
The methylation status of the ICR1 of the IGF2/H19
locus and of the ICR2 in the KCNQ1 gene was measured
with the Salsa MLPA kit ME030-B2 (MRC-Holland,
Amsterdam, Netherlands) [38-40]. The MS-MLPA
method [38] employed for the kit is a modification of
the original MLPA technique [39,40]. Specifically, MS-
MLPA kit ME030 was designed to detect and quantify
abnormal methylation ratios of the two imprinted
domains H19DMR (ICR1) and KvDMR (ICR2) as well as
deletions and duplications of one or more exons of the
11p15 genes. The basis of the method is the quantitative
PCR amplification of target DNA after restriction with a
DNA methylation-sensitive enzyme (HhaI) specific for
the CpG-containing sequence GCGC. HhaI cleaves only
unmethylated DNA, while a GCmethylGC sequence is re-
sistant to cleavage. For each investigated CpG site, a
PCR product of specific length surrounding the site is
obtained.
In each MS-MLPA reaction, five different sites named
M1 to M5 (Figure 1 and Additional file 1) from the
ICR1 and four different sites from the ICR2 (Additional
file 1) were analyzed simultaneously. For each reaction,
200 ng of genomic DNA was used. The extent of methy-
lation at a specific site (expressed in%) could becalculated from reference PCR reactions for genomic
sequences lacking a GCGC tetranucleotide and from a
parallel reaction of the same, but unrestricted genomic
DNA sample. The mean of the methylation values from
M1 to M5 was taken to characterize ICR1 methylation
as a whole, and correspondingly ICR2 methylation was
calculated as the mean of the methylation values from
the four KCNQ1 ICR2 sites. MS-MLPA results for ICR1
methylation correspond well with a bisulfite conversion-
based method for DNA methylation analysis using the
Humanmethylation27 bead array [31].
Fibroblast cell culture
Fibroblast cell cultures were established in RPMI
(Gibco) + 10% FCS (Biochrom, Berlin, Germany) + 100
units/ml penicillin/streptomycin (Biochrom). In brief,
2 mm skin punch biopsies were manually dissected into
five to ten tissue pieces and transferred to 1.5 ml medium
in a 25-cm2 cell culture flask (BD Falcon, Heidelberg,
Germany). After 8 to 10 days of culture, outgrowth of
fibroblasts from tissue pieces adherent to the flask bottom
was microscopically observed. At that time 5.5 ml
medium was added, and cultivation was continued. After
approximately 5 to 6 weeks of culture, cells reached con-
fluence and were trypsinized and passaged to 75-cm2
flasks. Further passages were done with 1:4 cell dilutions.
Fibroblasts from passages 4 to 8 were used for experi-
ments aimed at the quantification of ICR1 methylation
levels, secreted factors, specific mRNAs, cell proliferation,
or the generation of clonal cell lines. All experiments
were done in culture medium as above. Fibroblast cul-
tures were named according to the body side of origin
(S2L for example indicates the culture obtained from the
biopsy taken at the left arm of patient S2).
Starting from a single cell out of the cultured skin fibro-
blast, clonal cultures for SRS patient S2 and for control
individual K1 were generated. Single cells from strongly
diluted solutions of trypsinized fibroblasts were trans-
ferred with a micropipette under microscopic control into
single wells of 24 or 48 well plates (BD Falcon). Online
microscopic monitoring ensured that only one cell was
aspirated during the process of single cell picking. Cell
clones reaching confluence were trypsinized and culti-
vated in larger cell containers. Cell aliquots from clone
passage 4, corresponding to roughly 18 to 20 cell divisions
(2x105 to 106 cells) after single cell picking, were used for
DNA methylation analysis. No outgrowth of cells was
observed when cultivating medium volumes devoid of
cells aspirated from the diluted cell suspensions.
IGF2 and H19 mRNA quantification
IGF2 and H19 mRNA were quantified by real-time PCR
from reverse-transcribed whole fibroblast RNA. Trypsi-
nized fibroblasts were seeded at a density of 5,400 cells/
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in culture, whole cellular RNA was prepared from cells
directly lysed in lysis buffer (Qiagen RNeasy kit) includ-
ing 10% β-mercaptoethanol. After reverse transcription
(250 ng whole RNA per reaction, oligo dT priming; Invi-
trogen Superscript III kit) IGF2 and H19 transcripts were
quantified by real-time PCR (IQ Sybr Green Supermix
from Bio-Rad, München, Germany; Bio-Rad CFX0096
cycler) with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) normalization. Primer design was done with
NCBI Primer Blast. See Additional file 10 for sequences
of primers used.
IGF-II measurements in culture medium
Secretion of IGF-II by fibroblasts into the culture medium
was monitored with an in-house radioimmunoassay
(RIA) (range 0.31 to 40 ng/ml, intra/inter assay variation
8/8.6%). In each experiment, the culture medium not
incubated with the fibroblasts was also measured to de-
termine and subtract the background level due to cross-
reacting bovine IGF-II which was found to be at 3.5 to
5.3 ng/ml.
Trypsinized fibroblasts were seeded at a cell density of
6,250/cm2, corresponding to 60,000 cells/3 ml medium/
well of a 6-well plate (Falcon). After 1 day in culture, the
medium was changed. After 7 days in culture, supernatant
probes were taken and assessed as described above. Mean
values of 2 to 3 wells/culture were determined.
Fibroblast proliferation
To measure baseline proliferation rates under normal cul-
ture conditions, fibroblasts were seeded at 200 cells/well
(low cell density, 713 cells/cm2) or 1,600 cells/well (high
cell density, 5,700 cells/cm2) of three 96-well plates and
incubated for 1, 4, or 7 days. Cell proliferation was deter-
mined with the MTS test [41](Promega, Madison, WI,
USA) for one plate after 1 day in culture and for the par-
allel plates after 4 and 7 days in culture, respectively, by
photometry (absorption measurement at 490 nm with
reference wavelength 630 nm). Cell-free medium wells
incubated in parallel served as negative controls for back-
ground values. Absorption ratios day4/day1 and day7/day4
were calculated to determine proliferation rates. Mean
values of 3 wells/point/culture were calculated. For each
fibroblast culture, two experiments were performed.
To measure the extent of the stimulation of fibroblast
proliferation by IGF-I and IGF-II, different concentra-
tions of rhIGF-I and rhIGF-II (Gropep, Adelaide, Aus-
tralia) diluted in culture medium were added on day 4
to wells seeded on day 0 as described above. MTS test
and photometry followed on day 7. Values for the rela-
tive proliferative effect of the different hormone concen-
trations were determined by dividing the values for the
rhIGF-I/rhIGF-II-stimulated fibroblasts through thosefor fibroblasts treated with diluent only and grown in
parallel. Mean EC50 values for SRS and control cultures
were determined with help of the Sigma Plot software.Statistical analysis
For the levels of DNA methylation, IGF2 and H19
mRNA expression, and IGF-II protein amount, mean
deviations were calculated from multiple determinations
(relevant numbers given in the corresponding tables).
For mean values of subject groups, SD was calculated.
Statistical comparison between subject groups was done
by two-sided t-tests. P-values < 0.05 were regarded to be
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